Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
  • entries
    84
  • comments
    0
  • views
    134

More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications


Narender

3 views

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

 

To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030

 

The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:

§  Type of payment of licensing agreements

§  Upfront payments

§  Milestone payments

 

§  Type of protein degrader

§  Degronimids

§  PROTACs

§  SARDs / SERDs

§  Specific BET and DUB inhibitors

§  Other protein degraders

 

§  Therapeutic area

§  Neurodegenerative disorders

§  Oncological disorders

§  Other therapeutic areas

 

§  Route of administration  

§  Oral

§  Intravenous

§  Other routes

 

§  Key geographical region

§  North America

§  Europe

§  Asia-Pacific

 

The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:

§  Arvinas

§  Captor Therapeutics

§  Celgene

§  Genetech

§  Kymera Therapeutics

§  Mission Therapeutics

§  Progenra

§  Radius Health 

§  Sanofi Genzyme

§  Zenopharm

 

Table of Contents

 

1. Preface


2. Executive Summary


3. Introduction
 

4. Current Market Landscape
 

5. Company Profiles
 

6. Clinical Trial Analysis 
 

7. KOL Analysis
 

8. Publication Analysis
 

9. Funding and Investment Analysis
 

10. Partnerships and Collaborations
 

11.  Market Sizing and Opportunity Analysis
 

12. Executive Insights

 

13. Concluding Remarks

 

14. Appendix 1: Tabulated Data

 

15. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...